Singular Genomics Systems Inc
Singular Genomics Systems, Inc., a life science technology company, develops next generation sequencing and spatial multiomics technology for researchers and clinicians to advance science and medicine. It is involved in the developing of G4, consisting of G4 instrument and associated consumables for various applications, such as max read kits for single cell sequencing, rare variant detection wit… Read more
Singular Genomics Systems Inc - Asset Resilience Ratio
Singular Genomics Systems Inc (OMIC) has an Asset Resilience Ratio of 32.81% as of September 2024. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2019–2023)
This chart shows how Singular Genomics Systems Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down Singular Genomics Systems Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $61.21 Million | 32.81% |
| Total Liquid Assets | $61.21 Million | 32.81% |
Asset Resilience Insights
- Very High Liquidity: Singular Genomics Systems Inc maintains exceptional liquid asset reserves at 32.81% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Singular Genomics Systems Inc Industry Peers by Asset Resilience Ratio
Compare Singular Genomics Systems Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Beijing Centergate Technologies Holding Co Ltd
SHE:000931 |
Medical Instruments & Supplies | 0.06% |
|
Blue Sail Medical Co Ltd
SHE:002382 |
Medical Instruments & Supplies | 5.12% |
|
Andon Health Co Ltd
SHE:002432 |
Medical Instruments & Supplies | 35.75% |
|
Allmed Medical Products Co Ltd Class A
SHE:002950 |
Medical Instruments & Supplies | 3.78% |
|
Inix Technologies Holdings Bhd
KLSE:0094 |
Medical Instruments & Supplies | 0.06% |
|
Focus Point Holdings Bhd
KLSE:0157 |
Medical Instruments & Supplies | 2.30% |
|
Careplus Group Bhd
KLSE:0163 |
Medical Instruments & Supplies | 4.91% |
|
LKL International Bhd
KLSE:0182 |
Medical Instruments & Supplies | 0.38% |
Annual Asset Resilience Ratio for Singular Genomics Systems Inc (2019–2023)
The table below shows the annual Asset Resilience Ratio data for Singular Genomics Systems Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2023-12-31 | 59.41% | $157.71 Million | $265.47 Million | +7.48pp |
| 2022-12-31 | 51.93% | $170.31 Million | $327.98 Million | +13.08pp |
| 2021-12-31 | 38.85% | $138.17 Million | $355.65 Million | -11.08pp |
| 2020-12-31 | 49.93% | $15.23 Million | $30.50 Million | -34.54pp |
| 2019-12-31 | 84.48% | $40.70 Million | $48.17 Million | -- |